The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy
Open accessAbstract
Glycosylated “triple-interaction” stabilized siRNA nanomedicine ameliorated AD neuropathology by targeting BACE1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672
Drug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571
Hutchinson, E. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2985 · Cited by 532
Evidence for brain glucose dysregulation in Alzheimer's disease
An, Y., Varma, V. R., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.011 · Cited by 507
Li, R., Lindholm, K., Yang, L.-B., Yue, X., Citron, M., Yan, R., Beach, T., Sue, L., Sabbagh, M., Cai, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0205689101 · Cited by 496
Burrowing and nest building behavior as indicators of well-being in mice
Jirkof, P. (2014) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2014.02.001 · Cited by 438
Hydrophobic modifications of cationic polymers for gene delivery
Liu, Z., Zhang, Z., Zhou, C., & Jiao, Y. (2010) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2010.04.007 · Cited by 432
Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model
Singer, O., Marr, R. A., Rockenstein, E., Crews, L., Coufal, N. G., Gage, F. H., Verma, I. M., & Masliah, E. (2005) · Nature Neuroscience · doi:10.1038/nn1531 · Cited by 428
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 410
Facilitative glucose transporters: an expanding family
Gould, G. W., & Bell, G. I. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90125-u · Cited by 315
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
Bachurin, S. O., Bovina, E. V., & Ustyugov, A. A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21434 · Cited by 304
Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain
Anraku, Y., Kuwahara, H., Fukusato, Y., Mizoguchi, A., Ishii, T., Nitta, K., Matsumoto, Y., Toh, K., Miyata, K., Uchida, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00952-3 · Cited by 294
Self-citationBACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice
Ohno, M., Cole, S. L., Yasvoina, M., Zhao, J., Citron, M., Berry, R., Disterhoft, J. F., & Vassar, R. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.008 · Cited by 290
The role of glucose transporters in brain disease: Diabetes and Alzheimer’s disease
Shah, K., DeSilva, S., & Abbruscato, T. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012629 · Cited by 288
BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
Moussa‐Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H., & Al‐Tel, T. H. (2020) · Medicinal Research Reviews · doi:10.1002/med.21622 · Cited by 274
Desai, M. K., Sudol, K. L., Janelsins, M. C., Mastrangelo, M. A., Frazer, M. E., & Bowers, W. J. (2009) · Glia · doi:10.1002/glia.20734 · Cited by 266
Cancer nanomedicine: is targeting our target?
Lammers, T., Kiessling, F., Ashford, M., Hennink, W., Crommelin, D., & Storm, G. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.69 · Cited by 233
Zheng, M., Liu, Y., Wang, Y., Zhang, D., Zou, Y., Ruan, W., Yin, J., Tao, W., Park, J. B., & Shi, B. (2019) · Advanced Materials · doi:10.1002/adma.201903277 · Cited by 217
Self-citationBehavioral assays with mouse models of Alzheimer's disease: Practical considerations and guidelines
Puzzo, D., Lee, L., Palmeri, A., Calabrese, G., & Arancio, O. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.011 · Cited by 213
Nanotechnology-based strategies for siRNA brain delivery for disease therapy
Zheng, M., Tao, W., Zou, Y., Farokhzad, O. C., & Shi, B. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.01.006 · Cited by 210
Self-citationChallenges in DNA Delivery and Recent Advances in Multifunctional Polymeric DNA Delivery Systems
Shi, B., Zheng, M., Tao, W., Chung, R., Jin, D., Ghaffari, D., & Farokhzad, O. C. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00803 · Cited by 201
Self-citationMin, H. S., Kim, H. J., Naito, M., Ogura, S., Toh, K., Hayashi, K., Kim, B. S., Fukushima, S., Anraku, Y., Miyata, K., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201914751 · Cited by 201
Self-citationKlepper, J., & Voit, T. (2002) · European Journal of Pediatrics · doi:10.1007/s00431-002-0939-3 · Cited by 176
Does Nanomedicine Have a Delivery Problem?
Torrice, M. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00190 · Cited by 163
Zhang, R., Xue, G., Wang, S., Zhang, L., Shi, C., & Xie, X. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120151 · Cited by 160
Wang, P., Zheng, X., Guo, Q., Yang, P., Pang, X., Qian, K., Lu, W., Zhang, Q., & Jiang, X. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.034 · Cited by 158
Self-citationPrati, F., Bottegoni, G., Bolognesi, M. L., & Cavalli, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00393 · Cited by 140
Filali, M., & Lalonde, R. (2009) · Brain Research · doi:10.1016/j.brainres.2009.07.066 · Cited by 121
Xie, J., Gonzalez‐Carter, D., Tockary, T. A., Nakamura, N., Xue, Y., Nakakido, M., Akiba, H., Dirisala, A., Liu, X., Toh, K., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b09991 · Cited by 119
Self-citationClearance of two organic nanoparticles from the brain via the paravascular pathway
Gu, X. Q., Song, Q., Zhang, Q., Huang, M., Zheng, M., Chen, J., Wei, D., Chen, J., Wei, X., Chen, H., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.009 · Cited by 88
Self-citationThe Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Vassar, R., & Cole, S. (2007) · Current Genomics · doi:10.2174/138920207783769512 · Cited by 84
Wesson, D. W., & Wilson, D. A. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.08.033 · Cited by 78
Uno, Y., Piao, W., Miyata, K., Nishina, K., Mizusawa, H., & Yokota, T. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.083 · Cited by 76
Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story
Stamford, A. W., & Strickland, C. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.04.016 · Cited by 67
Inhibitor Discovery for the Human GLUT1 from Homology Modeling and Virtual Screening
Ung, P. M. U., Song, W., Cheng, L., Zhao, X., Hu, H., Chen, L., & Schlessinger, A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00304 · Cited by 55
Astrocytes from adult Wistar rats aged in vitro show changes in glial functions
de Souza, D. G., Bellaver, B., Raupp, G. S., Souza, D. O., & Quincozes-Santos, A. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.07.016 · Cited by 51
Versijpt, J. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132639 · Cited by 48
Axonal and Schwann Cell BACE1 Is Equally Required for Remyelination of Peripheral Nerves
Hu, X., Hu, J., Dai, L., Trapp, B. D., & Yan, R. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.5207-14.2015 · Cited by 42
Progress in Alzheimer's disease drug discovery: an update.
Williams, M. J. (2009) · PubMed · Cited by 38
Zhao, P., Qian, X., Nie, Y., Sun, N., Wang, Z., Wu, J., Chen, W., Ma, R., Wang, Z., Chai, G., et al. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00138 · Cited by 37
Nanomedicine and neurodegenerative disorders: so close yet so far
Tosi, G., Vandelli, M. A., Forni, F., & Ruozi, B. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1041374 · Cited by 23
Cited by
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
“Similar micelle-based strategies with surface modi fi cation of targeting ligands were performed for the synergistic chemotherapy of glioma, 269 gene therapy of Alzheimer ’ s disease, 270 and traumatic brain injury.”
MethodSelf-citationEmerging role of exosomes in cancer progression and tumor microenvironment remodeling
Paskeh, M. D. A., Entezari, M., Mirzaei, S., Zabolian, A., Saleki, H., Naghdi, M. J., Sabet, S., Khoshbakht, M. A., Hashemi, M., Hushmandi, K., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01305-4 · Cited by 563
Multifunctional mesoporous silica nanoparticles for biomedical applications
Xu, B., Li, S., Shi, R., & Liu, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01654-7 · Cited by 433
Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier
Zha, S., Liu, H., Li, H., Li, H., Wong, K.-L., & All, A. H. (2024) · ACS Nano · doi:10.1021/acsnano.3c10674 · Cited by 378
Gathering brings strength: How organic aggregates boost disease phototheranostics
Qi, J., Ou, H., Liu, Q., & Ding, D. (2021) · Aggregate · doi:10.1002/agt2.25 · Cited by 284
Metadata
- Authors
- Zhou, Y., Zhu, F., Liu, Y., Zheng, M., Wang, Y., Zhang, D., Anraku, Y., Zou, Y., Li, J., Wu, H., Pang, X., Tao, W., Shimoni, O., Bush, A. I., Xue, X., & Shi, B.
- Venue
- Science Advances
- Published
- 2020-10-09
- Volume
- 6
- Issue
- 41
- ISSN
- 2375-2548 (ISSN-L)
- OpenAlex
- W3092068755
- Cited by
- 300
- References
- 53
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.